Drugs / DF6002
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT04423029 | Jul 2020 → Nov 2025 | cancer | Dragonfly Therapeutics | Completed | No outcome recorded |
News releases announcing trial results or a regulatory action · 1
| Date | Issuer | Release |
|---|---|---|
| 2023-04-16 | Dragonfly Therapeutics | Results Dragonfly Therapeutics Announces the Publication of Preclinical Data dragonflytx.com ↗
Dragonfly's preclinical data demonstrates that DF6002 is well tolerated when administered systemically and results in potent anti-tumor responses in multiple preclinical models as monotherapy and in combination with checkpoint inhibitors. |
All press releases naming this drug 2 releases
| Date | Issuer | Release |
|---|---|---|
| 2023-04-16 | Dragonfly Therapeutics | Dragonfly Therapeutics Announces the Publication of Preclinical Data dragonflytx.com ↗ |
| 2023-02-05 | Dragonfly Therapeutics | Dragonfly Announces it now owns all rights to its DF6002 novel IL12 cytokine dragonflytx.com ↗ |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | DF6002 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04423029 ↗ |
| Route | Intravenous | “subcutaneous (SC) and intravenous (IV) administration of DF6002” NCT04423029 ↗ |
| Route | Subcutaneous | “subcutaneous (SC) and intravenous (IV) administration of DF6002” NCT04423029 ↗ |